Martek Biosciences (MATK) Had A Great Day Yesterday
Tweet
Share
E-mailGet Alerts MATK Hot Sheet
Join SI Premium – FREE
Martek Biosciences Corp (Nasdaq: MATK) performed well yesterday (rising over 15%) after it reported its fiscal fourth-quarter net income at $18.3 million, or 55 cents a share, up from $100,000, or less than 1 cent a share, in the same period a year earlier.
Martek\'s bottom line was boosted by a $10.8 million tax benefit. Martek\'s revenues grew more than 22% to $82 million in the three months ended Oct. 31.
Martek Biosciences Corporation develops omega-3 docosahexaenoic acid (DHA) products.
Martek\'s bottom line was boosted by a $10.8 million tax benefit. Martek\'s revenues grew more than 22% to $82 million in the three months ended Oct. 31.
Martek Biosciences Corporation develops omega-3 docosahexaenoic acid (DHA) products.
You May Also Be Interested In
- Deutsche sees a buying opportunity in this MedTech stock
- 5 reasons why you should buy the earnings dip in this retailer's stock
- Marvell earnings preview: Is a beat-and-raise quarter possible?
Create E-mail Alert Related Categories
Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
